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The aim of the present investigation was to improve the solubility and dissolution rate of
Iloperidone. Microspheres containing Iloperidone were prepared by spray drying using
mucilage extracted from seeds of Caesalpinia pulcherrima. The novelty of this work is that,
the extraction of mucilage and its usage for preparation of drug loaded microspheres. The
prepared microspheres were characterized by SEM, DSC, XRPD, FTIR, 1H-NMR, particle size,
drug content, entrapment efficiency, in vitro dissolution and ex vivo mucoadhesion. Based
on particle size, drug content, ex vivo mucoadhesive strength and in vitro drug release, the
best formulation was optimized. Percent entrapment efficiency and mean particle size for
optimized formulation was found to be 73.49 and 3.27 ± 1.23 mm, respectively. More pre-
cisely, mucilage of C. pulcherrima could be significant carrier of (drug and polymer ratio 1:5)
microspheres for the development of oral drug delivery.
Copyright 2015, Beni-Suef University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Solubility is amajor challenge for pharmaceutical scientists to
develop new pharmaceutical dosage form, since about 70% of
newly discovered and investigated drugs either insoluble or
poorly soluble in water and thus low oral bioavailability.
Water insoluble, poorly soluble drugs often require high doses
in order to reach therapeutic plasma concentrations after oral
administration (Wong et al., 2006; Keck and Muller, 2006;
Lipinski et al., 2006; Ige et al., 2013).harmaceutics & Quality
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licenses/by-nc-nd/4.0/).Microspheres and/or microparticles using spray drying
method are emerged as an important tool in drug delivery to
provide solution to these conflicts (Elzoghby et al., 2013;
Esposito et al., 2000; Patil et al., 2010; Palmieri and
Bonacucina, 2001; Vasir and Tambwekar, 2003).
In novel drug delivery, coupling of bioadhesive properties
to microspheres is of great importance because of additional
advantages of efficient absorption and enhanced bioavail-
ability of the drug, intimate contact with themucus layer and
reduction in frequency of drug administration due to theAssurance, R C Patel Institute of Pharmaceutical Education and
563 255189.
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adhering to mucosa (Prajapati and Jani, 2013).
Iloperidone is a second generation (atypical) antipsychotic
drug candidate which was approved by US FDA in May 2009.
The mechanism of action is unknown but its efficacy in
schizophrenia is mediated through a combination of dopa-
mine (D2) and serotonin (5-HT2) antagonisms. Iloperidone is
practically insoluble in water (0.00304 mg/mL), half life
(13.5e14 h) undergoes extensive first-pass metabolism and
demonstrates non-specific tissue distribution. Iloperidone is
rapidly absorbed after oral administration and reaches peak
plasma levels within 2e4 h (Mandpe and Pokharkar, 2013,
2014).
Polymers used for the microsphere preparation was the
mucilage extracted from seeds of Caesalpinia pulcherrima
(Mucilage-CP). Mucilage-CP is a natural and biodegradable
polymer having several advantages: non-toxic and non-
absorbable from the gastrointestinal tract, non-irritant to
the mucus membrane and form a strong non-covalent bond
with the mucin-epithelial cell surfaces. It provide a longer
contact time for drug transport across the mucus membrane
(Lersten and Curtis, 1993; Tonon and Brabet, 2008;
Suryawanshi et al., 2013;Thombre and Gide, 2014).
In the present investigations, the microspheres of lipo-
philic Iloperidone using natural mucoadhesive polymer was
prepared by spray drying method. The drug and polymer
identification and interaction were studied using differential
scanning calorimety (DSC), X-ray powder diffraction (XRPD)
and nuclear magnetic resonance (NMR). The prepared mi-
crospheres were characterized by encapsulation efficiency;
drug content, mean particle size, scanning electron micro-
scopy (SEM), motic microscopy, in vitromucoadhesion, in vitro
drug release and short term stability studies.
Novelty of this work is that first time use of the mucilage
extracted from seeds of C. pulcherrima were attempted and
prepared the mucoadhesive microspheres containing Iloper-
idone using spray drying method.2. Materials and methods
2.1. Materials
Iloperidone and Mannitol were received as gift sample from
pharmaceuticals, Vanda pharmaceuticals (Bombay, India) and
S. D. Fine Chemicals Ltd (Bombay, India), respectively. The
dried seeds of C. Pulcherrima plants were collected (extraction
of mucilage) from suburban and rural areas of Shirpur (Dhule,
India). All other reagents were of analytical grade and used
without further purification.
2.2. Methods
2.2.1. Isolation of mucilage from dried seeds of Caesalpinia
pulcherrima
The dried seeds of C. pulcherrimawere soaked in purifiedwater
for 24 h, boiled for 1 h and kept aside for 2 h to release
mucilage in to water. The material was squeezed in a muslin
bag to remove the marc from the filtrate. Then, equal volume
of acetone was added to filtrate to precipitate the mucilage.The mucilage was separated, dried in oven at 50 C, powdered
content and passed through sieve mesh 80. The powder was
stored in desiccator until further use.
2.2.2. Preparation of Iloperidone loaded microspheres
Iloperidone loaded microspheres based on mucilage-CP were
prepared by spray-drying of simple dispersion using a LU-222
Advanced Spray Dryer, Labultima, (Bombay, India) with a
standard 0.5mmnozzle (Table 3). Mucilage-CPwas solubilized
in purified water IP (50 mL) at 1% (w/v) concentration by
continuous stirring and gradually heated until the homoge-
nous solution was obtained. The drug was added in polymer
solution slowly with continuous stirring and subsequent
addition of small volumes of water until the uniform disper-
sion of drug and polymer solution. The dried product was then
collected in receiver. The processing variables for the spray
dryer was inlet air temperature about 120

C, outlet air tem-
perature about 80

C with feed pump rate at 4e6 mL/min at an
aspiration speed of 45 rpm.2.3. Drug and polymer conformation and compatibility
studies
2.3.1. Differential scanning colorimetry
Thermal analysis was conducted for the pure Iloperidone,
mucilage-CP and formulation IF5 using DSC (Mettler Toledo,
Switzerland). Thermographs were obtained at scanning rate
of 10 C/min over a temperature range of 40e300 C under an
inert atmosphere flushed with nitrogen flow rate at 30 mL/
min.
2.3.1.1. Calculation of glass transition temperature. Glass
transition was change in heat capacity of material. A simple
relaxation model for increase in heat capacity at the glass
transition is given by Equation (1),
Dh
dt
¼ exp

Dh 
RTg2

ðT TgÞ
 ðTDCp hÞ
tg2
(1)
where, h ¼ d þ TDCp
d ¼ the excess enthalpy relative to the equilibrium value,
DCp ¼ the heat capacity change at the glass transition,
Dh* ¼ the apparent activation energy, Tg ¼ the glass tem-
perature, and tg ¼ the relaxation time at equilibrium at Tg.
2.3.2. X-ray powder diffraction
The X-ray diffraction patterns of pure Iloperidone, mucilage-
CP and formulation IF5 were recorded on an X-ray diffrac-
tometer (Brucker Axs, D8 Advance, Germany). These samples
were irradiated with monochromatized Cu Ka radiation and
analyzed between 3 and 80 (2q). The voltage and current were
used 30 kV and 30 mA, respectively.
2.3.3. 1H-Nuclear magnetic resonance
In order to perform the 1H-NMR, the samples of Iloperidone
and mucilage-CP were prepared in suitable solvents and
respective spectra were recorded at 300 MHz in (Varian USA.)
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2.4.1. Drug content, encapsulation efficiency and production
yield
Accurately weighed 50 mg of microspheres were triturated
with 10 mL of purified water and allowed to stand for 10 min.
Methanol was added to produce 50 mL and sonicated for
3 min. The solution was then filtered, diluted suitably and
analyzed for drug content at 229 nm using spectrophotometer
(UV 1700, Shimadzu, Japan). Drug content and encapsulation
efficiency (EE) were calculated using Equation (2).
% EE ¼ Amount of drug entrapped
Amount of drug added
 100 (2)
The percent production yields of the respective batch were
calculated by the Equation (3).
% Production Yield ¼ Total Weight of Microspheres
Total Weight of RawMaterials
 100
(3)
2.4.2. Particle size analysis and scanning electron microscopy
The particle size and zeta potential of microspheres were
measured using dynamic light scattering zetasizer (Zetasizer
Nano ZS 90, MalvernLtd., UK). In order to get 100e200 kilo
counts per second for the measurement, each sample was
diluted with purified water in the ratio of 1:100. The
morphology of formulation IF5 was examined by scanning
electron microscopy (JSM 6390, Japan). Samples of micro-
spheres were dusted onto double-sided tape on an aluminum
stub and coated with gold using a cold sputter coater to a
thickness of 400 A˚, and imaged using a 20 kv electron beam.
2.4.3. Ex vivo mucoadhesion studies
In order to determine the mucoadhesive strength of the mi-
crospheres, the laboratory designed apparatus was subjected
to explored (Ige and Gattani, 2012). Microspheres were
equivalent to 5 mg of Iloperidone and hydrated with little
amount of purified water and dispersed on themucosal tissue
(goat intestinal tissue from slaughter house) and left on it for
30 min for interaction with mucosal surface. Mucoadhesive
strength using intestinal tissue was investigated in phosphate
buffer (pH 6.8) maintained at 37 ± 0.5 C. At the end, the mi-
crospheres were washed with phosphate buffer for 30 min at
the rate of 5 mL/min. Resultant solution was collected in
beaker and analyzed for drug content at 229 nm using UV
spectrophotometer.
2.4.4. In vitro drug release studies
Microspheres, equivalent to 10 mg of Iloperidone, from all the
respective batches, were filled into the dialysis bag and the
drug release was determined using USP XXVI paddle (Type II)
apparatus 4 (TDT-08L plus, Electrolab, Bombay, India). The
paddle was then immersed in the phosphate buffer (pH 6.8)
maintained at 37 ± 2 C andwas rotated at the speed of 50 rpm.
Sample aliquots of 5mLwerewithdrawn at each hour interval
for 4 h and respective sampleswere estimated at 229 nmusing
UV spectrophotometer. To explore the mechanism of drug
release from formulations, the data were treated as first order,
Higuchi's and Korsmeyer peppa's equation along with zero
order patterns.2.4.5. Short term stability studies
Optimized formulation batch IF5 in dry powder form filled in
nine different flint colored glass vials with rubber stoppers.
Three vials were kept environmental controlled stability
chamber maintained at 40 C ± 2 C and 75 ± 5% for the period
of 90 days. These sampleswere analyzed for particle size, drug
content, ex vivo mucoadhesion and in vitro dissolution pa-
rameters at 30 days interval.3. Results and discussion
3.1. Drug-polymer compatibility studies
3.1.1. Differential scanning colorimetry, X-Ray powder
diffraction and 1H-Nuclear magnetic resonance
Thermal behavior of the formulation IF5 exhibited melting
endotherm of Iloperidone at 117.2 C and backward shifting of
phase transition exotherm at 175e215 C was observed.
These studies revealed that there is no interaction between
drug and polymer with significant decrease percent crystal-
linity that leads to conversion of semi crystalline to amor-
phous nature (Fig. 1). Powder x-ray diffraction pattern was
used to qualitatively detect the material with long range or
sharper diffraction peaks which indicated more crystalline
material. The distinctive sharp peaks were observed at
diffraction angles 9, 12, 17, 18, 19, 20, and 22 on 2q scale,
which illustrated the typical amorphous nature of polymer.
The absence of crystalline peaks of polymer in formulation
IF5 confirmed that, the drug was molecularly dispersed in the
polymer and conversion of crystalline into the amorphous
form was achieved (Fig. 2). NMR study was confirmed the
protons in chemical structure of drug, polymer and physical
mixture (Tables 1 and 2). Individual spectra was compared
with respective spectra in physical mixture and revealed that
there were no structural differences observed in drug and
polymer.
3.2. Characterization of Iloperidone loaded microspheres
3.2.1. Drug content, encapsulation efficiency and production
yield
Percent production yields, drug content, encapsulation effi-
ciency and particle size of spray dried microspheres are
shown in Table 1. The production yields of microspheres were
gradually increased with respect to increase in drug and
polymer ratio and it was found to be in between 15.65 to
20.34%. The low production yield can be attributed due to the
low quantity of materials used for spray drying and loss of the
smaller particles through the exhaust of the spray-dryer
during the manufacturing process and to the adherence of
some liquid droplets extensively inside the glass wall of
cyclone. The low production yield of microspheres could also
be related to the higher viscosity of feeding solution tending to
reduce the spray nozzle efficiency and higher moisture con-
tent of prepared particles, results the loss of product in a film-
like deposit, which forms on the cyclone wall because of the
higher molecular weight and more hydrophilic structure of
polymer. However, the loss during spray drying might be
reduced significantly if the sample size is increased in
Fig. 1 e Thermal behaviour of the pure Iloperidone, mucilage-CP and formulation IF5.
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ratios did not substantially influenced the morphological
characteristics of the spray-dried particles. The drug encap-
sulation efficiencies were very close to the theoretical values
and it was found to be in between 63.2% and 73.49%. The
percent drug content was found to be 12.91 to 31.51. Polymer
concentration had influence on the drug content and encap-
sulation efficiency. As the drug and polymer ratio increased,
there was significant increase in encapsulation efficiency and
decrease in drug content. Preparation method showed good
reproducibility, as indicated by analysis of encapsulation ef-
ficiency and drug content carried out on all batches prepared
under identical conditions. All these results demonstrated
that, spray drying was the most suitable technique for the
preparation of Iloperidonemicrosphereswith appropriate size
and high encapsulation efficiency.Fig. 2 e X-ray diffractogram of (A) formulation IF3.2.2. Particle size analysis and scanning electron microscopy
Mean particle size of the different formulations of micro-
spherewas found to be 2.95 ± 1.05 to 3.27 ± 1.23 mm (Table 3). It
was found that the drug and polymer ratio had significant
effect on the particle size of microspheres. As the amount of
polymer was increased in the formulations, there was signif-
icant increase in particle size of microspheres (Fig. 4). The
microspheres of the prepared batches were negatively
charged; indicating the presence of CP-mucilage at the surface
of all the microspheres. The zeta potential of the optimized
batch was found to be 25 mv indicated the absence of ag-
gregation of microspheres. Surface topography of the opti-
mized microspheres IF5 batch was studied using SEM.
External morphology and surface texture of microspheres are
shown in Fig. 3. The external morphology showed nearly
spherical particles while the surface texture of the5, (B) Mucilage-CP and (C) pure Iloperidone.
Table 1 e Presenting types of proton, types of signals and
region of peak pure drug and pure polymer.
Types of protons in the drug Types of
signals
Region(d ppm)
Aryl proton Multiplet 7.6e8.0
Aryl proton Multiplet 7.0e7.5
Alicyclic proton Multiplet 1.8e2.2
Methylic proton Doublet 3.0
Methoxyl proton Multiplet 3.1
Aliphatic methylene proton Multiplet 3.4e4.2
Types of protons in the polymer Types of
signals
Region(d ppm)
Anomeric proton Doublet 3.475
Hydroxyl proton Doublet 2.539
Methyl proton Singlet 1.227
Table 2 e Presenting types of proton, types of signals and
d ppm values of physical mixture of drug and polymer
(ratio 1:1).
Types of proton Types of signals Region(d ppm)
Aromatic proton Multiplet 7.6e7.7
Aromatic proton Multiplet 7.0e7.42
Alicyclic proton Multiplet 1.6e2.19
Methylic proton Doublet 2.9
Methoxy proton Multiplet 3.18
Aliphatic methylene proton Multiplet 3.4e4.0
Anomeric proton Doublet 3.49
Hydroxyl proton Doublet 2.45
Methyl proton Singlet 1.6e2.19
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nature (Paradkar et al., 2002).
3.2.3. Ex-vivo mucoadhesion studies
Ex-vivo mucoadhesion study was performed for all the
formulation batches and %mucoadhesion are shown in Table
3. The microspheres containing a higher proportion of muci-
lage showed higher mucoadhesive strength.
3.2.4. In vitro drug release studies
Dissolution of different batches of spray dried microspheres
and bulk drug was carried out in phosphate buffer (pH 6.8).
Dissolution studies clearly confirmed that, significant in-
crease in the dissolution rates of microspheres (Fig. 5). For IF5
batch, about 43.37 % of the drug was dissolved at 2 h in
phosphate buffer (pH 6.8). While the remaining formulations
IF4, IF3, IF2, IF1 and bulk drug showed dissolution aboutTable 3 e Percent production yield, drug content, percent enca
particle size of different formulations of the Iloperidone loaded
Batch code Amount of
drug (gm)
Amount of
polymer (gm)
Drug
content (%)
Produ
yield
IF1 1.0 1.0 31.51 15
IF2 1.0 2.0 19.59 14
IF3 1.0 3.0 14.98 20
IF4 1.0 4.0 13.59 20
IF5 1.0 5.0 12.19 2029.14%, 26.05%, 22.41%, 13.37% and 7.86%, respectively. The
dissolution rate had enhanced due to reduction in particle size
and increase in surface area. Therefore, IF5 showed higher
saturation solubility amongst all batches.
3.2.5. Short term stability studies
Optimized formulation IF5 was subjected to stability studies
at accelerated conditions for a period of 90 days. After 90
days the particle size, % drug content, ex vivomucoadhesion
and % CDR were found to be 3.29 ± 1.25 mm, 12.16, 87.34 and
43.13, respectively. The results of stability studies showed
no significant change in particle size, % drug content, %
ex vivo mucoadhesion and % CDR. Henceforth, the opti-
mized batch IF5 was stable for 90 days at 40 ± 2 C and
75% ± 5% RH.
DSC and 1H NMR studies showed that there was no any
compatibility issue between mucilageeCP and Iloperidone. In
addition, DSC and XRPD studies revealed that, the amorphous
nature of drug in the prepared microspheres as compared to
semi-crystalline behavior of the bulk drug.
In the present investigations, mucoadhesive microspheres
of low water soluble Iloperidone was successfully prepared
and enhanced the dissolution rate by reducing the particle
size and by releasing the drug in uni-directional pattern to
increase the therapeutic efficacy. The spray drying technique
was an easy, reproducible and suitable method to obtain mi-
crospheres. This technique provides high encapsulation effi-
ciency, narrow particle size distribution and low level of toxic
residual organic solvent when compared to other encapsula-
tion methods.
The mucilage extracted from the dried seeds of C. pulcher-
rima was found to have mucodhesive properties to bind the
drug in mucosal lining for longer time. The liquid dispersion
was fed to the nozzle with peristaltic pump, atomized by the
force of the compressed air and blown together with a hot air
to the chamber where the solvent in the droplets was evapo-
rated and spray dried powder was formed.
Based on particle size, drug content, ex vivomucoadhesive
strength, in vitro drug release, the formulation batch IF5 was
selected as the optimized formulation. Percent entrapment
efficiency for optimized formulation IF5 was found to be 73.49
andmean particle size about 3.27 ± 1.23 mm. Themicrospheres
containing a higher proportion of mucilage showed higher
mucoadhesive strength. The hydrophilic polymer had the
ability to absorb water and swelled with formulation con-
taining a high proportion of mucilage, therefore, optimized
formulation IF5 batch was exhibited the highest mucoadhe-
sion about 87.2%.psulation efficiency, percent mucoadhesion and mean
microspheres.
ction
(%)
Entrapment
efficiency (%)
Mean Particle size
(mm) ± S.D.
Mucoadhesion
(%)
.65 63.2 2.95 ± 1.05 75.1
.56 59.4 2.24 ± 1.82 78.4
.57 64.95 2.27 ± 1.09 82.2
.19 69.38 3.24 ± 0.76 85.2
.34 73.49 3.27 ± 1.23 87.5
Fig. 3 e Photomicrographs of optimized formulation of the Iloperidone-loaded microspheres (IF5) at different
magnifications.
Fig. 4 e Microscopic images of different batches of
microspheres IF1, IF3 and IF5.
Fig. 5 e In- vitro dissolution profile of pure drug and
different formulations of the mucoadhesive microspheres
in buffer medium (pH 6.8).
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formulation IF5, showed significant increase in IF5 optimized
batch. This might be due to the coating of polymer. To eval-
uate the release mechanism, different kinetics such as zero
order, first order, Higuchi kinetics and Korsmeyer's Peppas
model were applied. It was found that the in vitro drug release
of IF5 formulation was best explained by Higuchi kinetics, as
the plots showed the highest linearity (R2 ¼ 0.966).4. Conclusion
The solubility and dissolution rate of Iloperidone loaded mi-
crospheres (IF5) had significantly improved as compared to
bulk drug. This might be accomplished due to encapsulation
of drug in mucoadhesive polymer. Therefore, mucilage of C.
pulcherrima could be significant carrier of (drug and polymer
ratio 1:5) microspheres for the development of oral drug
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